PremiumCompany AnnouncementsNyxoah Nears FDA Approval for Genio System Nyxoah anticipates FDA approval for Genio system in Q2 Nyxoah price target lowered to $15 from $17 at H.C. Wainwright PremiumThe FlyNyxoah price target lowered to $15 from $16 at Stifel Nyxoah Reports 2024 Financial Results and U.S. Launch Plans Nyxoah Sa’s Earnings Call: Efficacy and Expansion PremiumCompany AnnouncementsNyxoah to Present at Oppenheimer Healthcare Conference Nyxoah announces commercial launch of Genio system in the Middle East Nyxoah Launches Genio Therapy in Middle East with First UAE Implantation